Effective May 31, 2026, Indivior will discontinue availability for PERSERIS® (risperidone) extended-release injectable suspension (90 mg - 120 mg). Indivior has not taken this action due to safety or efficacy issues related to the product.
If you are a Healthcare Provider and have patients currently taking PERSERIS®, please plan to switch your patients to an alternate therapy or modify their treatment plan based on your clinical judgement. After May 31, 2026, it may be possible to obtain PERSERIS® for a few more months depending upon supplier inventory.
If you are a patient currently taking PERSERIS®, please discuss options for alternate treatment with your Healthcare Provider.
Our medical team is available to answer any medical inquiries to PERSERIS you might have. They can be reached at infoMIU@indivior.com or by calling 1-877-782-6966. Also, to report adverse events related to PERSERIS®, please call us at 1-877-782-6966 or email us at: PatientSafetyNA@Indivior.com.
Full prescribing information for PERSERIS® is available at:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210655s014lbl.pdf
Thank you for your continued commitment to patient care.
Share